Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – Yahoo Finance
Vancouver, British Columbia–(Newsfile Corp. – November 2, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in…
Vancouver, British Columbia–(Newsfile Corp. – November 2, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response…
-
Noosa News20 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News19 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General23 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General14 hours ago‘Potential’ hacker contacts Qantas over data breach